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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
Primary objective
To assess the effectiveness of health promotion interventions in community pharmacy practice settings on pharmacy workers and
pharmacy clients (including diagnosed patients) when compared to
i) No treatment controls
ii) Usual treatment controls
iii) Other active intervention
Secondary objectives
To assess whether there are differences in effectiveness of health promotion interventions in community pharmacy practice settings on
i) Pharmacy worker
ii) Client (patient)
with regard to:
i) Ethnicity of patients
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ii) Country income level (World Bank Group 2009)
iii) Extent of adverse health behaviour (defined according to national guidelines where available)
iv) Type of pharmacy worker delivering the intervention (e.g. pharmacist versus pharmacist technician)
v) Theoretical constructs/components and behaviour change techniques employed in the intervention
vi) Costs of health care
B A C K G R O U N D
Description of the condition
Pharmacists are the third largest regulated healthcare professional
group in the world (Chan 2006), with community pharmacy
themost commondiscipline represented. Community pharmacies
have been identified as an easily accessible and cost-effective plat-
form for delivering health care worldwide (DOH 2005; WHO
1998). For example, in England there are over 12,000 community
pharmacies; crucially, 99% of the population - even those living
in deprived areas - can access a pharmacy within a 20 minute drive
(DOH 2008). In Australia, over 90% of the population visit a
pharmacist over the course of a year (Benrimoj 2004). Similarly, in
low- and middle-income countries pharmacies are often seen as ‘a
first point of call’ for advice on symptoms and for early diagnosis
of illness (Smith 2009).
In view of the wide accessibility of community pharmacists, the
role has undergone rapid expansion in recent years (WHO 2006).
In addition to dispensing and medication-linked services, phar-
macies are now required to give advice on public health priorities,
including modification of health behaviour to minimise risk of
disease and to promote a healthy lifestyle (DOH 2005). Smoking
cessation was one of the earlier behaviour change tasks given to
pharmacists in the UK, and now others have been added such as
improving general lifestyle behaviours, increasinguptake of screen-
ing and giving sexual health advice (RPSGB 1996). To address the
needs of this changing role and to maintain high standards, inter-
national guidance for good pharmacy practice has been published
which stresses health promotion as one of six components which
contribute to the health improvement of individuals that access
community pharmacy services (WHO 2011).
However, despite this potential, the evidence base underpinning
these wider health promotion tasks is currently relatively poor,
both for effective methods of changing professional practice and
to evaluate the health gains that could result from these changes.
Research evidence suggests that whilst pharmacists and consumers
hold positive attitudes to pharmacist involvement in public health,
pharmacist confidence is currently low and additional training
needs are perceived (Eades 2011).
Systematic reviews examining behaviour change interventions by
clinical topic have thus far been limited by small numbers of poor
quality studies (Gordon 2011; Sinclair 2004; Watson 2006), sug-
gesting that a broad overview of studies of health promotion in-
terventions in pharmacies is needed both to inform current phar-
macy practice and to identify areas for future research.
Description of the intervention
TheWorld Health Organization defines health promotion as “the
process of enabling people to increase control over, and to improve,
their health”. The idea of health promotion moves beyond a focus
on individual behaviour towards a wide range of social and envi-
ronmental interventions (WHO 2009). Interventions that target
a specific aspect of lifestyle, such as smoking cessation, or that
address wider aspects of clinical management, such as overweight
and obesity or type 2 diabetes mellitus, therefore fall within this
definition.
Interventions to address these broad health promotion and be-
haviour change tasks amongst people attending community phar-
macies may be directed at pharmacy staff, their clients (or pa-
tients), or at both groups. The types of intervention may vary
from educational programmes (Sarayani 2012), to specific train-
ing in particular behavioural issues, such as readiness to change be-
haviour (Sinclair 1998). Other interventions target management
of medical conditions by patients, for example monitoring blood
pressure (Fikri-Benbrahim 2012) or managing asthma (Armour
2007). These types of interventions go well beyond the traditional
remit of pharmacy workers, which conventionally focused on the
dispensing and management of medicines.
Previous Cochrane reviews (Nkansah 2010; Pande 2013) have
examined non-dispensing services in pharmacies; however, these
have still had a strong focus onmedications, including ‘medication
reviews’ or medication therapy management interventions. Such
interventions provide person-centred care and consider the med-
ication regimen, including issues of adherence. To avoid overlap
with previous work, we will exclude any purely medication-related
interventions in this review. We will also exclude studies that only
use behavioural techniques to address adherence to medication.
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How the intervention might work
The way in which health promotion and behaviour change in-
terventions work within community pharmacy is likely to be de-
pendent on the theoretical basis for the intervention and the be-
haviour change techniques they use (Michie 2008). For example,
interventions may aim to increase self efficacy in performing a be-
haviour that promotes health, or may examine ways of overcom-
ing barriers to performing that behaviour. The behavioural theory
underpinning interventions and the mechanisms by which com-
munity pharmacy interventions might work have not previously
been studied in detail. However, an understanding of the mecha-
nisms by which health behaviour change is achieved in successful
community pharmacy interventions, and the behaviour change
theories used, will be important in designing more effective inter-
ventions, both for existing clinical areas and to support the expan-
sion of the role of the pharmacist in the future.
The current review will therefore seek to identify which underpin-
ning theories and behaviour change techniques are most effective
in achieving health behaviour change in a community pharmacy
setting. We aim to identify generic methods that could be used
to inform development of any health promotion intervention in
a community pharmacy setting.
Most interventions involve training the pharmacist or pharmacy
worker; however, evidence is sparse regarding the best methods of
training pharmacists in health behaviour change techniques. Even
if pharmacists and pharmacy staff can be trained effectively and
can deliver the intervention with fidelity, there still remains the
question of whether clients (or patients) follow the given advice
and, further, whether this results in meaningful improvements in
health and well-being. There has been no previous comprehensive
review of the effectiveness of community pharmacy staff as agents
for health behaviour change (Anderson 2003). It is important to
consider the complete pathway from intervention to effects on
health outcomes. Hence we will examine study outcomes related
both to the professional behaviour of pharmacy staff and to health
promotion in their clients.
Why it is important to do this review
This review is important because pharmacists worldwide are in-
creasingly taking on health promotion as part of their rapidly ex-
panding role in delivery of primary health care. However research
evidence supporting the use of pharmacists as agents for changing
health behaviours is sparse, and thus the best ways of enabling
pharmacists to perform this new role and the magnitude of the
health benefits that might accrue for their patients are both un-
certain. Similar uncertainty surrounds the optimum structure of
pharmacy-based health promotion interventions and their costs.
This review aims to address gaps in existing knowledge, highlight-
ing ways in which current clinical practice can be improved and
suggesting areas where further research is needed.
We will examine all relevant studies where pharmacists or phar-
macy staff (pharmacy technicians, pharmacy assistants) deliver an
intervention to improve the health behaviour of people attend-
ing community pharmacies. The review will study the impact of
the intervention on changing professional practice and effecting
health behaviour change in patients or members of the public (col-
lectively called ’clients (patients)’ here). We shall also collate evi-
dence on the methods of training pharmacists and pharmacy staff
and will consider whether any specific approaches are associated
with greater effectiveness in changing professional behaviour or
patient-based outcomes.
The review will include high-, middle- and low-income country
settings and will consider whether effectiveness differs by country
income group. Pharmacies provide an existing health infrastruc-
ture with a client base, supply chains and trained health profes-
sionals in countries where other forms of primary care are poorly
developed. Evidence to support expansion of their clinical role in
low- and middle-income countries could be important in plan-
ning use of healthcare resources globally.
The reviewwill also evaluate whether effectiveness of interventions
varies by ethnicity or by the extent of the adverse health behaviour
(e.g. number of cigarettes smoked per day), as it is important to
understand whether a ‘one size fits all’ approach is effective, or
whether there is evidence of differential effectiveness of the inter-
vention in people with particular characteristics. For example, in
asthma self management there is evidence that culturally specific
interventions for different ethnic groups are more effective than
generic programmes (Bailey 2009). Thus, this review will consider
whether there is likely to be a benefit in stratifying people for tar-
geted health promotion interventions in a community pharmacy
setting.
The review will also evaluate whether the type of pharmacy worker
delivering the intervention has an impact on the effectiveness of
the intervention (e.g. pharmacist versus pharmacist assistant). A
previous review has stressed the importance of training of facil-
itators for the effectiveness of self-management education pro-
grammes for chronic conditions (Foster 2007). Thus the current
review will evaluate whether the level of qualification and experi-
ence of the pharmacy worker has an impact on the effectiveness of
the intervention on clients’/patients’ behaviour change and health
outcomes.
O B J E C T I V E S
Primary objective
To assess the effectiveness of health promotion interventions in
community pharmacy practice settings on pharmacy workers and
pharmacy clients (including diagnosed patients) when compared
to
i) No treatment controls
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ii) Usual treatment controls
iii) Other active intervention
Secondary objectives
To assess whether there are differences in effectiveness of health
promotion interventions in community pharmacy practice set-
tings on
i) Pharmacy worker
ii) Client (patient)
with regard to:
i) Ethnicity of patients
ii) Country income level (World Bank Group 2009)
iii) Extent of adverse health behaviour (defined according to na-
tional guidelines where available)
iv)Type of pharmacyworker delivering the intervention (e.g. phar-
macist versus pharmacist technician)
v) Theoretical constructs/components and behaviour change tech-
niques employed in the intervention
vi) Costs of health care
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and cluster-
RCTs comparing the intervention to usual practice or to control
intervention(s). We will also include non-randomised controlled
trials, controlled before-after (CBA) studies and interrupted time
series (ITS) studies, in line with Cochrane Effective Practice and
Organisation of Care (EPOC) group recommendations (EPOC
Guidance on Study Designs), and as it is expected that a num-
ber of studies will have utilised these designs. In line with EPOC
recommendations (EPOC Guidance on Study Designs), cluster-
RCTs and CBA studies will only be eligible if there are at least two
intervention sites and two control sites. ITS studies will only be
eligible if there is a clearly defined point in time when the inter-
vention occurred and at least three data points before and three
after the intervention. Publication status of study (i.e. abstract, full
text, unpublished data) will not be a bar to inclusion (Chandler
2013).
Types of participants
Participants in this reviewwill be workers within community phar-
macy settings, defined as regulated outlets outside a secondary
healthcare setting, which are under the direction of a pharmacist.
We will include interventions directed at any worker within the
pharmacy including pharmacists and other workers such as phar-
macy technicians and assistants. We will exclude studies where
participants are from a hospital or non-community-based phar-
macy, e.g. outpatient clinic setting. Where studies have mixed set-
tings we will only include them if the majority of pharmacy staff
took part in a community setting or if the community subset was
analysed independently. Similarly, where the intervention is mul-
tidisciplinary we will only includes studies if i) the majority of
the intervention was delivered in community pharmacy, or ii) the
community pharmacy aspect of the intervention was evaluated
separately, e.g. change in community pharmacists behaviour.
Types of interventions
We will include any health promotion intervention targeted at, or
delivered by, community pharmacy staff with the aimof improving
health behaviours of individuals attending the pharmacy.
We will exclude studies if the intervention is solely focused on
medication.This includes those interventions only concernedwith
prescriptions of medication, medication review, or adherence to
medication. Where medication management is only one compo-
nent of an intervention and other behavioural aspects (e.g. diet or
exercise) are targeted, then we will include these interventions.
We will exclude studies in which interventions do not involve
active interaction between pharmacy staff and their clients (e.g.
displays of leaflets/posters on lifestyle in the pharmacy).
We will describe interventions in terms of:
• Mode of delivery (e.g. video/ DVD, one-to-one or group-
based or web-based sessions); agent delivering the intervention
(e.g. pharmacist, pharmacy assistant);
• Setting (e.g. on site in pharmacy); duration (including
length and number of sessions and period over which
intervention delivered); incentives and/or reimbursement of
pharmacy staff;
• Theoretical basis as classified by the Theoretical Domains
Framework (Cane 2012) and defined by Michie 2010, and
behaviour change techniques - classified using the 93-item
Behaviour Change Taxonomy (v1) (Michie 2012);
• Content (e.g. smoking cessation, lifestyle
recommendations, condition management, pharmaceutical
prescription/no medication)
We will also document the intervention fidelity where this was
assessed. Where necessary, we will contact authors of studies to
obtain additional details of interventions and training of pharmacy
staff.
Comparison interventions will be those where i) no treatment is
received, ii) usual treatment but not the intervention is received,
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or iii) where another active intervention is received, for example
comparison of small-group education versus large-group educa-
tion.
Types of outcome measures
Primary outcomes
To assess the effects of community pharmacy interventions on
health promotion by pharmacy staff, we will look at three cate-
gories of outcomes:
1) Professional practice outcomes, 2) Client (patient) outcomes,
3) Adverse effects.
1. Professional practice outcomes will primarily be behavioural
and will include:
• Uptake of intervention by pharmacy staff, adherence to the
intervention (e.g. number of clients asked about smoking status),
change in behaviour, e.g. inhaler technique.
• Social-cognitive process outcomes such as pharmacists’
knowledge of the subject area.
2. Client (patient) outcomes will include assessment of:
• Health status and well-being, including i) intermediate
outcomes, e.g. cholesterol, glycated haemoglobin, ii) clinical
outcomes, e.g. stroke, myocardial infarction, iii) psychological
health, e.g. anxiety and depression, iv) psychosocial outcomes,
e.g. quality of life.
• Health behaviours, e.g. smoking, exercise, inhaler
technique.
• Socio-cognitive process outcomes such as knowledge,
satisfaction.
3. Adverse effects which will include any adverse events defined as
such by the included studies, either at the professional or partici-
pant level.
In line with EPOC recommendations (EPOC 2002), we will only
include studies where at least one outcome is assessed using an ob-
jective or validated tool. For assessment of pharmacist behaviour
simulated patients are considered a recognised and objective mea-
surement tool and will therefore be included (Watson 2006; Xu
2012).
Secondary outcomes
Wewill include costs, as reported in primary studies, as a secondary
outcome. This will include direct and indirect healthcare costs
including scheduled and unscheduled visits to other healthcare
providers.
Search methods for identification of studies
Electronic searches
The Effective Practice and Organisation of Care (EPOC) Trials
Search Co-ordinator (TSC) will write the search strategies in con-
sultation with the authors. The TSC will search the Cochrane
Database of Systematic Reviews and the Database of Abstracts of
Reviews of Effects (DARE) for related systematic reviews, and will
search the following databases for primary studies.
• Cochrane Central Register of Controlled Trials
(CENTRAL)
• Health Technology Assessment Database, Cochrane Library
• NHS Economic Evaluation Database, Cochrane Library,
Issue
• MEDLINE, 1950-, In-process and other non-indexed
citations, OvidSP
• EMBASE, 1947- , OvidSP
• PsycINFO, 1950-
• EPOC Group, Specialised Register
A draft search strategy for MEDLINE is provided in Appendix
1. We will test this strategy by screening selected citations for rel-
evance, and will validate it using a selection of exemplar papers
on the topic of this review. We will present the finalised strat-
egy in the review. We will modify the MEDLINE strategy for
other databases using appropriate syntax and vocabulary for those
databases. We will limit results by two methodological filters: the
Cochrane Highly Sensitive Search Strategy (sensitivity- and preci-
sion-maximising version - 2008 revision) to identify randomised
trials, and an EPOC methodology filter to identify non-RCT de-
signs. We will apply no limits by date or language.
Searching other resources
We will conduct a grey literature search to identify studies not
indexed in the databases listed above. Sources will include the sites
listed below. We will document additional sources, if any, in the
review.
• Open Grey (www.opengrey.eu)
• ProQuest Dissertations & Theses Full Text
• ProQuest Dissertations & Theses: UK & Ireland
Trial Registries
We will search the following Registries:
International Clinical Trials Registry Platform (ICTRP), Word
Health Organization (WHO): www.who.int/ictrp/en/
ClinicalTrials.gov, US National Institutes of Health (NIH): clini-
caltrials.gov/
We will also:
• Review reference lists of all included studies, relevant
systematic reviews/primary studies/other publications.
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• Contact authors of relevant studies or reviews to clarify
reported published information/seek unpublished results/data.
• Conduct cited reference searches for all included studies in
citations indexes.
Data collection and analysis
Selection of studies
We will import results of each search into the reference manage-
ment software package Endnote 2013. One review author will re-
move duplicates and screen titles and abstracts for obvious irrele-
vance to the review, e.g. not intervention study. A second review
author will complete sequential 10% checks of titles and abstracts
until we achieve an inter-rater reliability of 0.75 or greater (excel-
lent agreement (Orwin 1994)). The emphasis will be on over-
inclusion at this stage. We will then retrieve potentially relevant
papers and two review authors will screen all of these against the
inclusion criteria.We will present any studies excluded at this stage
in a ’Characteristics of excluded studies’ table, with reasons for
exclusion given. We will resolve any disagreements through dis-
cussion, referring where necessary to a third review author for ar-
bitration. We will treat multiple publications from a single study
as a single intervention evaluation.
We will document the full screening process in a PRISMA flow-
chart, presenting details of initial hits, hits following de-duplica-
tion, studies excluded at title abstract screening stage, studies ex-
cluded at full-text screening stage and final included studies.
Data extraction and management
Wewill extract data from eligible studies using a tailored extraction
form based on the generic Cochrane Effective Practice and Organ-
isation of Care (EPOC) Review Group data collection checklist
(EPOC 2002) and including the following data:
• Study details: Author, year, research question, country
where research was carried out; inclusion and exclusion criteria;
study design (RCT, cluster-RCT, controlled before-after study
(CBA), interrupted time series (ITS)); recruitment method (e.g.
self referral, advertisement); description of usual care.
• Intervention details: Intervention target (pharmacy staff
and/or clients), behavioural target (smoking, diet, exercise, etc);
health condition targeted, intervention description (mode of
delivery; theoretical basis; behaviour change techniques (Using
93-item BCT taxonomy (Michie 2012)).
• Pharmacy worker details: number, age, socioeconomic
status, ethnicity, gender, time since qualification.
• Client/Patient details: number, age, socioeconomic status,
ethnicity, gender, time since diagnosis (where applicable).
• Quality Criteria (in line with EPOC recommendations
EPOC Guidance on Risk of Bias).
• Results in primary and secondary outcomes.
Two review authors will independently and in duplicate extract
key information (inclusion criteria, e.g. design, participants, in-
terventions and outcomes, quality criteria and results) from each
included paper. One review author will extract other data and an-
other will check them.We will resolve any errors or disagreements
through discussion, with recourse to a third review author for ar-
bitration, and if necessary by discussion among the full author
group. One review author will enter data into Review Manager 5
(RevMan 2012), and a second review author will check them.
Assessment of risk of bias in included studies
We will assess the risk of bias in accordance with the Cochrane
Collaboration’s ’Risk of bias’ assessment tool (Higgins 2011a) and
in line with the EPOC groups ‘suggested risk of bias criteria for
EPOC reviews’ (EPOCGuidance on Risk of Bias). There are nine
standard criteria for all RCTs, non-RCTs and CBA studies, which
relate to the following questions:
i) Was the allocation sequence adequately generated?
ii) Was the allocation adequately concealed?
iii) Were baseline outcome measurements similar?
iv) Were baseline characteristics similar?
v) Was the study adequately protected against contamination?
vi) Were incomplete outcome data adequately addressed?
vii) Was knowledge of the allocated interventions adequately pre-
vented during the study?
viii) Was the study free from selective outcome reporting?
ix) Was the study free from other risks of bias?
For interrupted time series (ITS) studies we will use seven criteria.
These include items vi) - ix) above, as well as three further ques-
tions:
Was the intervention independent of other changes?
Was the shape of the intervention effect prespecified?
Was the intervention unlikely to affect data collection?
We will score each study as being at low, high or unclear risk (if
not specified in the paper). For some studies it may not have been
possible to blind participants to the intervention, e.g. an exercise
intervention, but we will still record this in the quality assessment.
Two review authors will assess each study’s quality, comparing
results and resolving discrepancies by discussion and by recourse
to a third review author if necessary. We will measure inter-rater
agreement using Cohen’s kappa coefficient (Uebersax 1987). We
will present the results both graphically and in a ‘Risk of bias’ table.
Measures of treatment effect
For continuous data we will estimate treatment effect sizes as stan-
dardised mean differences (SMDs) for each outcome, or weighted
mean difference if studies have a common outcome measure. We
will treat available data as continuous unless there is a defensible
cut-point available by which it may be considered dichotomous.
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Where dichotomous data are available, we will estimate the rela-
tive risk (RR) and the 95% confidence interval (CI) for all point
estimates. For CBA studies, in order to maximise data from indi-
vidual studies we will extract the baseline and final measurements
as well as the change scores with associated standard deviations for
continuous outcomes. Where dichotomous data are reported we
will extract the relative risk as available. Where adjusted estimates
are reported, we will also extract the factors being adjusted for. For
ITS studies, we will extract and report immediate change in level/
trend and associated standard deviation estimates. We will include
change in level estimates in any subsequent meta-analysis. We will
prefer final value scores to change scores where both are presented.
Unit of analysis issues
Where cluster-randomised trials are included we will consider
whether any unit of analysis errors are made. Where such errors
are identified we will perform a re-analysis using the information
on the size or number of clusters and the value of the intra-cluster
correlation coefficient (ICC) where the information is available.
When ITS studies are analysed using inappropriate statistical
methods or statistical analysis is not performed, we will re-analyse
the results (where possible). For re-analysis we will extract data on
individual observations over time from tables of results or graphs
presented in the original study. We will use time series regression
to re-analyse the results from each study. We will use model speci-
fication Outcome = constant + + β1time period + β2phase + β3*
time period * phase, using Stata version 12.1 (Higgins 2011b).
Thus it may be possible to perform an approximately correct anal-
ysis.
Dealing with missing data
Where a study has missing data we will in the first instance con-
tact the authors and request any additional data they may have,
including on training and content of interventions. If missing data
are still present we will calculate standard deviations for changes,
where possible. When there is insufficient information available
to calculate the standard deviations, we will impute missing stan-
dard deviations for changes from baseline using other information
available (e.g. correlation coefficients) (Higgins 2011b).
For dichotomous data where possible we will derive missing treat-
ment estimates and standard errors from the number of par-
ticipants included/randomised and the numbers with outcomes.
Where possible, we will use confidence intervals to derive missing
standard error estimates.
Assessment of heterogeneity
Given the diverse nature that behavioural interventions can take,
we anticipate some heterogeneity between studies. We will assess
this both qualitatively (for example, examining intervention char-
acteristics, study populations, context, etc) as well as quantita-
tively. We will investigate non-statistical heterogeneity by inspect-
ing forest plots for poorly overlapping confidence intervals of the
results of individual studies. We will discuss possible reasons for
heterogeneity and will assess the influence of those identified in-
dividual studies in sensitivity analyses.
We will formally assess the extent of statistical heterogeneity using
the Cochran’s Q statistic and corresponding Chi² and I² statis-
tics. This latter describes the percentage of the variability in effect
estimates that is due to heterogeneity rather than sampling error
(chance) (Higgins 2003).
Assessment of reporting biases
To test for publicationbiaswewill draw funnel plots, assuming that
standard errors and a unitary measure of effect can be produced, if
more than 10 studies are identified for a given outcome. We will
visually inspect funnel plot asymmetry and will discuss possible
reasons.
Data synthesis
We will give details of all included studies in a ‘Characteristics of
included studies’ table, irrespective of whether measured outcome
data are reported in a useable way.
For the main analysis, we will split outcomes into those examining
the effect on pharmacy staff and those examining the effect on
clients (patients).
In the first instance, we will consider the suitability of studies
for meta-analysis. If there is evidence of heterogeneity, it may be
misleading to conduct ameta-analysis. In that case wewill conduct
a narrative synthesis of studies and will present descriptive and
summary data of interventions.
Wheremeta-analysis is deemed appropriate, given there is likely to
be heterogeneity in terms of intervention, setting, and population,
we will adopt the more conservative random-effects model, unless
there is little suggestion of heterogeneity, when we would use a
fixed-effect model. If an outcome was measured at different times
in the same study, we will select the value nearest the endpoint of
the intervention period. When there are related outcomes from
the same study we will use the outcome most consistent across
studies (e.g. SF-36 above condition-specific measures) or the most
clinically rigorous measure (e.g. HbA1c above fasting blood glu-
cose). In this way we will pool only a single effect size for each
study. We will use Review Manager 5 software (RevMan 2012) to
collate data and perform calculations.
For eachmain comparison wewill prepare a ’Summary of findings’
table. We will use EPOC worksheets 1 - 4 to define the most im-
portant outcomes and use the GRADE approach to assess quality
for each included outcome.
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Subgroup analysis and investigation of heterogeneity
We will conduct subgroup analyses in RevMan. We will consider
whether there are different effects from studies conducted within
low- and middle-income countries (LMICs) compared with high-
income countries (HMICs). We will also examine whether people
from particular ethnic groups and those at extremes of adverse
health behaviour (e.g. heavy smokers) are more likely to respond
to pharmacy-based interventions. If there are sufficient studies
we will also explore whether theory-based interventions are more
effective than those not based on theory, and whether a financial
incentive influences effectiveness.
Meta regression
We will perform meta-regression where there are an adequate
amount of data, using Stata 12.1. This will consider which features
of interventions are more likely to be successful and will examine:
1) How the intervention is delivered (e.g. single brief consulta-
tion, several brief consultations plus follow-up telephone contact,
extended consultation);
2) Behaviour change techniques (Michie 2012) and underpinning
behaviour change theory where this is stated (or the likely under-
pinning behaviour change theory where this is not explicitly stated
(Michie 2010)).
Sensitivity analysis
We will conduct sensitivity analyses by excluding studies assessed
as being at high risk of bias, where standard deviations are im-
puted, or by varying the ICC for re-analysis of data from clus-
ter-randomised trials. We will also exclude studies contributing to
non-statistical heterogeneity, i.e. studies with poorly overlapping
confidence intervals for their results.This will involve undertaking
themeta-analysis twice, both with and without the studies in ques-
tion. We will examine Individual forest plots, but presentation of
sensitivity analyses will be in terms of a summary table.
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Appendix 1. Medline Search Strategy
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present>
--------------------------------------------------------------------------------
1 Community Pharmacy Services/ [Combine with Filters & Screen all] (2660)
2 ((pharmacy or pharmacist? or pharmacies) adj3 (community or counsel$ or advice or care)).ti. (2221)
3 (pharmacist? adj3 (front line or “one to one” or face to face)).ti,ab. (34)
4 (community adj2 pharmacist?).ab. (1256)
5 or/1-4 [Community Pharmacist] (4320)
6 Pharmacy/ or Pharmacists’ Aides/ or Pharmacists/ (17979)
7 (pharmacist? or pharmacy or pharmacies).ti. (21057)
8 (pharmacist? or (pharmacy adj3 (aide or aides or assistant? or staff ))).ab. (15609)
9 or/6-8 [Pharmacists/Pharmacies] (37873)
10 Community Health Services/ or Community Mental Health Services/ or Community networks/ or exp Counseling/ or Family
Planning Services/ (99363)
11 exp Maternal Health Services/ [part of Community Health Services] (33717)
12 schools/ or students/ (49141)
13 (community or communities).ti. (100290)
14 (community adj3 (care or healthcare or health care or service or services)).ab. (17873)
15 or/10-14 [community] (270495)
16 Patient Education as Topic/ or exp health education/ or consumer health information/ or health fairs/ (132424)
17 “tobacco use cessation”/ or smoking cessation/ (19729)
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18 self care/ or blood glucose self-monitoring/ (26231)
19 health promotion/ or healthy people programs/ or weight reduction programs/ (51960)
20 exp Mass Screening/ (97458)
21 (smoking cessation or (quit$ adj2 smok$)).ti,ab. (17945)
22 patient care.ti,ab. (37361)
23 (patient? adj3 (educat$ or counsel$ or helping or advising or directing or caring or assist? or assisting or assistance or teaching or
learning or promoting)).ti,ab. (50821)
24 (patient? adj2 (advice or counsel$ or program? or programme or programmes or workshop? or session?)).ti,ab. (16803)
25 (consumer? adj3 (advice or educat$ or counsel$ or helping or advising or directing or caring or care or assist? or assisting or assistance
or teaching or learning or promoting)).ti,ab. (2983)
26 (health adj2 (improv$ or promotion)).ti,ab. (43998)
27 partner$.ti,ab. (100595)
28 ((weight gain or weight loss or (weight adj2 (losing or gaining)) or obesity or obese or addicted or addiction? or smoking or lifestyle
or blood pressure or self-care) adj3 (educat$ or counsel$ or helping or advising or directing or caring or assist? or assisting or assistance
or teaching or learning or promoting)).ti,ab. (10046)
29 deleted line
30 ((cholesterol or blood pressure or blood sugar or glyc?em$ or asthma$ or eating or diet or inhaler? or diabet$ or immuni?ation? or
vaccination? or screening or self-manag$ or hypertension) adj3 (control$ or counsel$ or manage$ or education$)).ti,ab. (123593)
31 or/16-28,30 [Patient Ed, Health Promotion--proxy terms for interventions conducted in community pharmacy settings]
(615267)
32 deleted line
33 Professional Role/ (7926)
34 ((role or roles) adj2 (chang$ or new or pharmacy or pharmacies or pharmacist?)).ti,ab. (12440)
35 or/33-34 [Professional Role] (19902)
36 (9 and 15) not 5 [Pharmacists/Pharmacies & Community] (1012)
37 (9 and 31) not (or/5,36) [Pharmacists/Pharmacies & Patient Ed] (3905)
38 (and/9,35) not (or/5,36-37) [Pharmacists & Role] (1313)
39 (randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or ran-
domly.ab. or trial.ti. (872795)
40 exp animals/ not humans.sh. (3869593)
41 39 not 40 [Cochrane RCT Filter 6.4.d Sens/Precision Maximizing] (805144)
42 5 and 41 [RCT Community Pharmacy MeSH Set 1] (452)
43 36 and 41 [Pharmacists/Pharmacies & Community & RCT: Set 2] (97)
44 37 and 41 [Pharmacists/Pharmacies & Patient Ed & RCT : Set 3] (399)
45 38 and 41 [Pharmacists & Role & RCT: Set 4] (58)
46 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational
or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$
or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy
or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or
tailor$ or target$ or team$ or usual care)).ab. (153300)
47 (pre-intervention? or preintervention? or “pre intervention?” or post-intervention? or postintervention? or “post intervention?”).ti,ab.
[added 2.4] (9542)
48 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing
or doctor?).ti,hw. (698954)
49 demonstration project?.ti,ab. (1913)
50 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$” or (pre adj5 post)).ti,ab. (62958)
51 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (582)
52 trial.ti. or ((study adj3 aim?) or “our study”).ab. (600821)
53 (before adj10 (after or during)).ti,ab. (347556)
54 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or ((quasi$
or experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw. (98088)
55 (“time series” adj2 interrupt$).ti,ab,hw. (962)
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56 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or
hour? or day? or “more than”)).ab. (8547)
57 pilot.ti. (38095)
58 Pilot projects/ (79317)
59 (clinical trial or controlled clinical trial or multicenter study).pt. (611602)
60 (multicentre or multicenter or multi-centre or multi-center).ti. (27823)
61 random$.ti,ab. or controlled.ti. (726448)
62 (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or study)).ab. not
(controlled clinical trial or randomized controlled trial).pt. (395608)
63 (control year? or experimental year? or (control period? or experimental period?)).ti,ab. [Added May 30-2013] (13197)
64 evaluation studies as topic/ or prospective studies/ or retrospective studies/ [Added Jan 2013] (923092)
65 (utili?ation or programme or programmes).ti. [Added Jan 2013] (53169)
66 (during adj5 period).ti,ab. [Added Jan 2013] (291762)
67 ((strategy or strategies) adj2 (improv$ or education$)).ti,ab. [Added Jan 2013] (17390)
68 (purpose adj3 study).ab. (217816)
69 “comment on”.cm. or review.pt. or (review not “peer review$”).ti. or randomized controlled trial.pt. [Changed Jan 2013] (2828940)
70 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti,hw. or veterinar$.ti,ab,hw.
[Edited May 2013] (5333261)
71 exp animals/ not humans.sh. (3869593)
72 (or/46-68) not (or/69-71) [EPOCMethods Filter 2.6] (2743232)
Results to Export--EPOC Filter
73 (5 and 72) not (or/42-45) [Community Pharmacy MeSH: EPOC Set 1] (1768)
74 (36 and 72) not (or/42-45) [Pharmacists/Pharmacies & Community & EPOC Set 6] (418)
75 (37 and 72) not (or/42-45) [Pharmacists/Pharmacies & Patient Ed & EPOC : Set 7] (1737)
76 (38 and 72) not (or/42-45) [Pharmacists & Role & EPOC: Set 8] (429)
Results to Export--RCT Filter
77 or/42-45 [RCT Export] (1006)
78 remove duplicates from 77 (1004)
79 (9 and (primary adj2 care).ti. and (or/41,72)) not (or/73-77) (89)
80 remove duplicates from 79 (89) [Primary Care & Pharmacist/Pharmacy & Filters--Exported]
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